Thermo Fisher Scientific | TMO - Equity Capital And Reserves


Thermo Fisher Scientific reported $51.93B in Equity Capital and Reserves for its fiscal quarter ending in March of 2026.





Equity Capital And Reserves Change Date
Abbott USD 52.06B 69M Mar/2026
Agilent USD 7.36B 241M Jun/2026
Becton, Dickinson and Co. USD 24.42B 283M Jun/2026
Bio Techne USD 2.11B 22.92M Jun/2026
Bio-Rad Laboratories USD 7.17B 322.6M Jun/2026
Boston Scientific USD 24.93B 934M Jun/2026
Bruker USD 2.44B 67M Jun/2026
Charles River Laboratories USD 2.84B 59.06M Jun/2026
Danaher USD 52.58B 368M Jun/2026
Dentsply International USD 1.35B 33M Jun/2026
Edwards Lifesciences USD 10.62B 290.5M Jun/2026
General Electric Aerospace USD 17.64B 417M Jun/2026
Henry Schein USD 3.16B 109M Jun/2026
Illumina USD 2.84B 162M Jun/2026
Intuitive Surgical USD 18.17B 693.9M Jun/2026
IQVIA Holdings USD 6.17B 50M Jun/2026
Laboratory Of America USD 8.61B 121.8M Jun/2026
Medtronic USD 50.23B 160M Jun/2026
Mettler Toledo International USD 12.82M 54.71M Jun/2026
Myriad Genetics USD 303.9M 33.5M Jun/2026
Olympus JPY 747.9B 64.14B Jun/2026
OraSure Technologies USD 317.78M 4.45M Jun/2026
Quest Diagnostics USD 7.52B 150M Jun/2026
Repligen USD 2.11B 6.57M Jun/2026
Revvity USD 7.18B 67.62M Mar/2026
Stryker USD 22.98B 559M Mar/2026
Thermo Fisher Scientific USD 51.93B 1.6B Mar/2026
Veracyte USD 1.39B 44M Jun/2026
Waters USD 15.29B 12.73B Mar/2026
Zimmer Biomet Holdings USD 12.63B 49.1M Jun/2026